Welcome to our dedicated page for Surgery Partners SEC filings (Ticker: SGRY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Surgery Partners, Inc. filings document the public-company record for a healthcare services operator focused on short-stay surgical facilities. Form 8-K reports furnish quarterly and annual results, non-GAAP reconciliations, guidance updates and Regulation FD materials related to the company’s surgical facility operations.
The filing record also covers governance and capital structure. Proxy materials describe director elections, executive compensation and stockholder voting matters, while current reports disclose debt financing through Surgery Center Holdings, Inc., supplemental indentures for senior notes, leadership appointments, employment agreements and the company’s Nasdaq-listed common stock.
Surgery Partners, Inc. director Dean Lloyd H filed an initial Form 3 reporting his beneficial ownership in the company. The filing shows that, as of February 26, 2026, he reported 0 shares of Surgery Partners common stock held directly.
Surgery Partners, Inc. filed a Rule 144 notice to sell 14,574 common shares, listed as equity vesting transactions on 02/28/2026 (2,939 shares) and 03/02/2026 (11,635 shares).
Shares outstanding were 129,419,836 as of 03/06/2026, as shown in the excerpt.
Surgery Partners, Inc. notice of proposed sale of 272 common shares under equity compensation, dated 03/02/2026, with UBS Financial Services Inc. listed as the broker.
The filing also reports a prior sale of 1,794 common shares on 03/05/2026 by William T. Webb.
UBS Financial Services Inc filed a Form 144 notice for proposed sales of common stock of Surgery Partners, Inc. (SGRY). The filing lists equity-vesting related shares: 5,291 shares vested 02/28/2026 and 6,171 shares vested 03/02/2026. The filing date shown is 03/06/2026 and the listing venue is NASDAQ.
Surgery Partners, Inc. disclosure: a Form 144 notice lists 8,785 shares of common stock for sale on 03/06/2026 in connection with equity vesting. The filing shows two vesting entries: 1,738 shares (02/28/2026) and 7,047 shares (03/02/2026).
Surgery Partners, Inc. filed a Form 144 disclosing proposed sales of vested common shares by an affiliate/broker. The excerpt lists 1,039 shares vesting on 02/28/2026 and 6,697 shares vesting on 03/02/2026.
Transactions are presented as equity compensation vesting and proposed resale under Form 144.
Surgery Partners, Inc. filed a Form 144 notifying an intended sale of common stock, including 2,117 and 7,965 shares that vested on 02/28/2026. The filing lists UBS Financial Services Inc. as the broker on Nasdaq transactions.
Surgery Partners, Inc. reports that its surgical facilities generated approximately $3.2 billion in revenue during 2025, driven by a national network of more than 200 locations in 30 states, including 157 ambulatory surgery centers and 19 surgical hospitals.
The company focuses on high-volume, non-emergency outpatient procedures across specialties such as orthopedics, pain management, ophthalmology and gastroenterology, and pursues growth through physician partnerships, acquisitions, and new facility development. As of December 31, 2025, it owned or operated 176 surgical facilities and employed about 16,000 people.
Revenue is highly dependent on third-party payors: in 2025, consolidated surgical facilities derived 52.3% of patient service revenue from private insurance and 42.8% from government programs, with management highlighting significant exposure to Medicare, Medicaid, and evolving health policy. The filing also details regulatory and reimbursement risks, including the One Big Beautiful Bill Act’s Medicaid changes and the expiration of Affordable Care Act subsidies, which may increase the uninsured population and pressure margins.
Surgery Partners, Inc. reported higher 2025 revenue but remained unprofitable while setting cautious 2026 goals and launching a new share repurchase program.
Full-year 2025 revenue rose 6.2% to $3.31 billion, with same-facility revenue up 4.9% driven by 3.4% same-facility case growth and a 1.4% increase in revenue per case. Adjusted EBITDA increased 3.5% to $526.2 million, but net loss attributable to Surgery Partners was $77.9 million, though this improved from a larger loss in 2024.
Fourth-quarter 2025 revenue grew 2.4% to $885.0 million, while Adjusted EBITDA slipped 4.2% to $156.9 million, reflecting margin pressure. The company ended 2025 with $239.9 million of cash and total net debt to EBITDA of about 4.3x under its credit agreement.
For 2026, management targets Adjusted EBITDA of at least $530 million and revenue between $3.35 billion and $3.45 billion, implying modest organic growth after factoring provider tax and tariff headwinds. The board also authorized a new share repurchase program of up to $200 million of common stock, signaling confidence while the company focuses on higher-acuity procedures, portfolio optimization and reducing leverage.